Ypsomed and BD expand partnership to address rapidly growing biologics market

Ypsomed and BD (Becton, Dickinson and Company), a leading global medical technology company, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak XtraFlow glass prefillable syringe. This innovation is designed to be fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform, expanding options for pharmaceutical companies and patients who require large‑volume subcutaneous self‑injections.  

Meeting the needs of today and tomorrow’s biologics  The new BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe leverages BD advanced technologies, including a shorter, 8-millimeter needle and thinner wall cannulas, to support the delivery of higher volume and viscosity medicines. These enhancements should enable improved injection time and optimized flow, addressing common challenges with large-volume biologics and enabling drug developers to move beyond the limitations of standard syringe offerings.